What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort

Bacci, M.; Quéro, L.; Barbier, E.; Parrot, Laurène; Juguet, F.; Pommier, P.; Bazire, Louis; Etienney, Isabelle; Baba-Hamed, Nabil; Spindler, Louise; François, Ετιεννε; Ronchin, P.; Campo, Eleonor Rivin del; Lemanski, C.; Lièvre, Astrid; Siproudhis, L.; Abramowitz, Laurent; Lepage, Côme; Vendrely, V.

doi:10.1016/j.dld.2021.03.015

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the French guidelines, exclusive radiotherapy is considered an option for T1 and T2 less than 3 cm without nodal involvement. Regarding T1 tumors, however, clinical practices are heterogenous between local resection, exclusive radiotherapy, inguinal irradiation omission, or chemoradiation with reduced radiotherapy doses as we showed in our previous analysis of this subgroup from the ANABASE cohort (29). In the UK, the ongoing trials ACT3 and ACT 4 investigate different radiotherapy doses for early-stage SCCA in the single-protocol « umbrella platform » PLATO (PersonaLising Anal cancer radioTherapy dOse, ISRCTN88455282).…”

Section: Chemoradiation With Imrt and Concurrent Chemotherapy Regimen...mentioning

confidence: 99%

Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE

Vendrely

Lemanski

Pommier

et al. 2023

Radiotherapy and Oncology

View full text Add to dashboard Cite

Section: Chemoradiation With Imrt and Concurrent Chemotherapy Regimen...mentioning

confidence: 99%

Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE

Vendrely

Lemanski

Pommier

et al. 2023

Radiotherapy and Oncology

View full text Add to dashboard Cite

“…Indeed, over 85% of patients who had excision had T1-T2 disease. Although beyond the scope of this manuscript, we acknowledge the controversy regarding the role of local excision in the management of patients with very early stage SCCA 26 .…”

Section: Discussionmentioning

confidence: 99%

Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution

et al. 2022

View full text Add to dashboard Cite

Background Although intensity-modulated radiation therapy (IMRT) is considered the standard of care for the treatment of squamous cell carcinoma of the anus (SCCA), few large series have reported oncologic outcomes and toxicities. In this retrospective report, we aim to describe outcomes and toxicities after IMRT-based chemoradiation (CRT) for the treatment of SCCA, evaluate the impact of dose escalation (>54 Gy), and compare concurrent fluoropyrimidine in combination with either mitomycin or with cisplatin as chemosensitizers. Methods Patients treated at The University of Texas MD Anderson Cancer Center between January 1, 2003 and December 31, 2018 with IMRT-based CRT were included. Median time to locoregional recurrence, time to colostomy, and overall survival were estimated using the Kaplan–Meier method. Results A total of 428 patients were included; median follow-up was 4.4 years. Three hundred and thirty-four patients (78.0%) were treated with concurrent cisplatin and fluoropyrimidine, and 160 (37.4%) with >54 Gy. Two- and 5-year freedom from locoregional failure, freedom from colostomy failure, and overall survival were 86.5% and 81.2%, respectively, 90.0% and 88.3%, respectively, and 93.6% and 85.8%, respectively. Neither dose escalation nor mitomycin-based concurrent chemotherapy resulted in improved outcomes. Mitomycin-based concurrent chemotherapy was associated with in approximately 2.5 times increased grade 3 or greater acute toxicity. Radiation dose >54 Gy was associated with approximately 2.6 times increased Grade 3 or greater chronic toxicity. Conclusions Our results suggest IMRT-based CRT with concurrent fluoropyrimidine and cisplatin is a safe and feasible option for patient with SCCA and may cause less acute toxicity. The role for radiation dose escalation is unclear and requires further study.

show abstract

Capecitabine

2021

Reactions Weekly

View full text Add to dashboard Cite

What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort

Cited by 3 publications

References 30 publications

Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE

Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE

Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution

Capecitabine

Contact Info

Product

Resources

About